Eli Lilly and Company has announced its acquisition of SiteOne Therapeutics, a move aimed at advancing non-opioid pain treatments and expanding its pipeline for pain therapies. The deal includes the development of STC-004, a promising investigational therapy targeting chronic pain. This acquisition aligns with Eli Lilly’s broader strategy to address unmet needs in pain management through innovative approaches that do not rely on opioids.
The transaction is expected to bolster Eli Lilly’s efforts in creating next-generation treatments for pain conditions. STC-004, the centerpiece of this acquisition, is designed to provide relief for chronic pain sufferers without the risks associated with opioid-based medications. By integrating SiteOne Therapeutics’ expertise and resources into its operations, Eli Lilly aims to accelerate research and development in this area. The company has expressed its commitment to addressing the growing demand for safer and more effective pain management solutions.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
Date: May 28, 2025
發佈留言